Other research analysts have also issued reports about the company. Liberum Capital restated a buy rating on shares of PureTech Health in a research report on Tuesday, November 27th. Jefferies Financial Group raised their price target on PureTech Health from GBX 245 ($3.20) to GBX 255 ($3.33) and gave the stock a buy rating in a research report on Tuesday, September 11th. Five research analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and an average target price of GBX 268.75 ($3.51).
Shares of PRTC traded up GBX 4 ($0.05) during midday trading on Thursday, hitting GBX 180 ($2.35). 69,581 shares of the stock were exchanged, compared to its average volume of 71,917. PureTech Health has a 52-week low of GBX 111.50 ($1.46) and a 52-week high of GBX 183.50 ($2.40).
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Featured Article: What are the Different Types of Leveraged Buyouts?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.